Blue­bird hopes for 3 drug ap­provals by 2019, in­clud­ing CAR-T and gene ther­a­pies

Blue­bird bio is hop­ing for an FDA OK for three of its ex­per­i­men­tal drugs by 2019, in­clud­ing the CAR-T bb2121 part­nered with Cel­gene hat caused a buzz at ASH.

That’s ac­cord­ing to the com­pa­ny’s CEO Nick Leschly, who an­nounced blue­bird’s am­bi­tious plans dur­ing his pre­sen­ta­tion at JPM.

The CAR-T, meant to treat mul­ti­ple myelo­ma, is a new BC­MA-tar­get­ing ther­a­py that has post­ed some stel­lar clin­i­cal re­sults in an ear­ly-stage study. The FDA al­ready gave the pro­gram break­through ther­a­py des­ig­na­tion. The CAR-T was the star of ASH when blur­bird re­port­ed ex­treme­ly high re­sponse and re­mis­sion rates with good safe­ty in a small study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.